ALQGC Quantum Genomics

Quantum Genomics (ALQGC) has announced that the results of its Phase IIb NEW-HOPE study will be presented in a late-breaking presentation at the American Heart Association (AHA) annual meeting on 10 November 2018.  Late-breaking presentations are typically reserved for results that are of high interest or impact and this presentation will help increase the profile of both Quantum Genomics and firibastat with physicians, potential partners and investors. We view it as positive that the trial enrolled much faster than expected and that the results will be presented at AHA in a late-breaking presentation.

We have increased our valuation of Quantum Genomics to €284m or €23.71 per share from €281m or €23.46 per share, mainly due to rolling forward our NPVs, although this was partly mitigated by a reduction in net cash.  We expect to update our valuation following the presentation on 10 November and the investor call on 12 November. The company had €6.0m in cash and investments at the end of H118 and has approximately €23.3m available in an equity line from Kepler Cheuvreux, which the company believes will fund it through the end of 2020. Click here to view the full report.

All reports published by Edison are available to download free of charge from its websitewww.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Maxim Jacobs, +1 646 653 7027Briana Warschun, +44 (0)203 5077 5700Healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:  LinkedIn          https://www.linkedin.com/company/edison-investment-research Twitter             www.twitter.com/Edison_Inv_Res YouTube         www.youtube.com/edisonitv